CRISPR Therapeutics (CRSP) – Investment Analysts’ Recent Ratings Changes

A number of research firms have changed their ratings and price targets for CRISPR Therapeutics (NASDAQ: CRSP):

• 7/17/2026 – CRISPR Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 7/8/2026 – CRISPR Therapeutics had its “buy” rating reaffirmed by HC Wainwright. They now have a $80.00 price target on the stock.
• 7/6/2026 – CRISPR Therapeutics had its “market outperform” rating reaffirmed by Citizens Jmp. They now have a $80.00 price target on the stock.
• 7/5/2026 – CRISPR Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.
• 6/27/2026 – CRISPR Therapeutics was upgraded by Wall Street Zen from “sell” to “hold”.
• 6/13/2026 – CRISPR Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.
• 6/12/2026 – CRISPR Therapeutics was given a new $80.00 price target by UBS Group AG.
• 6/11/2026 – CRISPR Therapeutics was given a new $60.00 price target by Morgan Stanley. They now have an “equal weight” rating on the stock.
• 5/27/2026 – CRISPR Therapeutics had its “market outperform” rating reaffirmed by Citigroup Inc..

Insider Activity at CRISPR Therapeutics

In related news, insider Naimish Patel sold 3,786 shares of the company’s stock in a transaction on Friday, May 29th. The stock was sold at an average price of $55.62, for a total transaction of $210,577.32. Following the completion of the sale, the insider directly owned 19,357 shares in the company, valued at $1,076,636.34. This represents a 16.36% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 4.30% of the company’s stock.

Get CRISPR Therapeutics AG alerts:

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.

Featured Stories

• Five stocks we like better than CRISPR Therapeutics
• Strait of Hormuz Tensions Spike Tanker Trade: These 2 Stocks Are Set to Benefit
• Shopify’s Quiet AI Strategy Could Be Its Biggest Advantage Yet
• Why These 3 Nuclear ETFs Are Getting a Fresh Look as AI Power Demand Rises
• 3 Aerospace Suppliers That Could Benefit as Aircraft Makers Face Bottlenecks

Receive News & Ratings for CRISPR Therapeutics AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics AG and related companies with MarketBeat.com's FREE daily email newsletter.